Donald M. Engelman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Donald M. Engelman has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
Oleg A. Andreev
Department of Physics, University of Rhode Island, Kingston, RI 02881
15 shared publications- Oleg A. Andreev
Physics Department, University of Rhode Island, Kingston, RI, United States
14 shared publications - Yana K. Reshetnyak
Physics Department, University of Rhode Island, 2 Lippitt Road, Kingston, Rhode Island 02881, United States
14 shared publications Yana K. Reshetnyak
Physics Department, University of Rhode Island, Kingston, RI 02881
9 shared publicationsAnna Moshnikova
Physics Department, University of Rhode Island, Kingston, RI 02881
8 shared publicationsDhammika Weerakkody
Department of Physics, University of Rhode Island, Kingston, RI 02881
7 shared publications
Latest Publications
- Open Access
- 13 March 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1355893
Aiming the magic bullet: targeted delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides
The family of pH (Low) Insertion Peptides (pHLIP) comprises a tumor-agnostic technology that uses the low pH (or high acidity) at the surfaces of cells within the tumor microenvironment (TME) as a targeted biomarker. pHLIPs can be used for extracellular and intracellular delivery of a variety of imaging and therapeutic payloads. Unlike therapeutic delivery targeted to specific receptors on the surfaces of particular cells, pHLIP targets cancer, stromal and some immune cells all at once. Since the TME exhibits complex cellular crosstalk interactions, simultaneous targeting and delivery to different cell types leads to a significant synergistic effect for many agents. pHLIPs can also be positioned on the surfaces of various nanoparticles (NPs) for the targeted intracellular delivery of encapsulated payloads. The pHLIP technology is currently advancing in pre-clinical and clinical applications for tumor imaging and treatment.
- 13 March 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1355893
Open AccessAiming the magic bullet: targeted delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides
The family of pH (Low) Insertion Peptides (pHLIP) comprises a tumor-agnostic technology that uses the low pH (or high acidity) at the surfaces of cells within the tumor microenvironment (TME) as a targeted biomarker. pHLIPs can be used for extracellular and intracellular delivery of a variety of imaging and therapeutic payloads. Unlike therapeutic delivery targeted to specific receptors on the surfaces of particular cells, pHLIP targets cancer, stromal and some immune cells all at once. Since the TME exhibits complex cellular crosstalk interactions, simultaneous targeting and delivery to different cell types leads to a significant synergistic effect for many agents. pHLIPs can also be positioned on the surfaces of various nanoparticles (NPs) for the targeted intracellular delivery of encapsulated payloads. The pHLIP technology is currently advancing in pre-clinical and clinical applications for tumor imaging and treatment.
- 1 January 2022
- Published by H1 Connect in Faculty Reviews
- Vol. 11
Structural basis of ER-associated protein degradation mediated by the Hrd1 ubiquitin ligase complex
- 1 January 2022
- Published by H1 Connect in Faculty Reviews
- Vol. 11
Structural basis of ER-associated protein degradation mediated by the Hrd1 ubiquitin ligase complex
- Open Access
- 28 December 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (1)
Pharmacokinetic modeling reveals parameters that govern tumor targeting and delivery by a pH-Low Insertion Peptide (pHLIP)
Significance: Tumors exhibit an acidic extracellular microenvironment that is accentuated at cell surfaces. As a result, they can be targeted by a pH-Low Insertion Peptide (pHLIP), an acid-triggered tumor-targeting peptide that can also serve as a vehicle for drug delivery. In this work, we use a pharmacokinetic modeling approach to deepen our understanding of the mechanisms and factors that influence pHLIP tumor targeting and delivery, and also identify factors that do not. In so doing, we predict pHLIP phenotypes with significantly enhanced capabilities. The model may therefore be useful for guiding the future development of pHLIP variants.
- 28 December 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (1)
Open AccessPharmacokinetic modeling reveals parameters that govern tumor targeting and delivery by a pH-Low Insertion Peptide (pHLIP)
Significance: Tumors exhibit an acidic extracellular microenvironment that is accentuated at cell surfaces. As a result, they can be targeted by a pH-Low Insertion Peptide (pHLIP), an acid-triggered tumor-targeting peptide that can also serve as a vehicle for drug delivery. In this work, we use a pharmacokinetic modeling approach to deepen our understanding of the mechanisms and factors that influence pHLIP tumor targeting and delivery, and also identify factors that do not. In so doing, we predict pHLIP phenotypes with significantly enhanced capabilities. The model may therefore be useful for guiding the future development of pHLIP variants.
- 14 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (22) , 12095-12100
Kinetics of pHLIP peptide insertion into and exit from a membrane
Significance: The process of peptide insertion across a membrane is of fundamental interest. Obtained in this study’s results, combined with our recent constant-pH molecular dynamics simulations and kinetics experiments with liposomes of different bilayer thicknesses, allowed us to complete a generalized model of the insertion/exit and folding/unfolding of polypeptides of the pHLIP family and expand the general view of peptide conformations and dynamic excursions of the bilayer that can accompany interactions with peptides. In addition to fundamental significance, pH-dependent pHLIP insertion into membranes of acidic cells within diseased tissues finds wide application in medicine for targeted delivery of imaging and therapeutic agents.
- 14 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (22) , 12095-12100
Kinetics of pHLIP peptide insertion into and exit from a membrane
Significance: The process of peptide insertion across a membrane is of fundamental interest. Obtained in this study’s results, combined with our recent constant-pH molecular dynamics simulations and kinetics experiments with liposomes of different bilayer thicknesses, allowed us to complete a generalized model of the insertion/exit and folding/unfolding of polypeptides of the pHLIP family and expand the general view of peptide conformations and dynamic excursions of the bilayer that can accompany interactions with peptides. In addition to fundamental significance, pH-dependent pHLIP insertion into membranes of acidic cells within diseased tissues finds wide application in medicine for targeted delivery of imaging and therapeutic agents.
- 19 December 2019
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (2) , 461-471
Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide
Tumor-targeted drug delivery systems offer not only the advantage of an enhanced therapeutic index, but also the possibility of overcoming the limitations that have largely restricted drug design to small, hydrophobic, “drug-like” molecules. Here, we explore the ability of a tumor-targeted delivery system centered on the use of a pH-low insertion peptide (pHLIP) to directly deliver moderately polar, multi-kDa molecules into tumor cells. A pHLIP is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pHLIPs target the acidic tumor microenvironment with high specificity, and a drug attached to the inserting end of a pHLIP can be translocated across the cell membrane during the insertion process. We investigate the ability of wildtype pHLIP to deliver peptide nucleic acid (PNA) cargoes of varying sizes across lipid membranes. We find that pHLIP effectively delivers PNAs up to ∼7 kDa into cells in a pH-dependent manner. In addition, pHLIP retains its tumor-targeting capabilities when linked to cargoes of this size, although the amount delivered is reduced for PNA cargoes greater than ∼6 kDa. As drug-like molecules are traditionally restricted to sizes of ∼500 Da, this constitutes an order-of-magnitude expansion in the size range of deliverable drug candidates.
- 19 December 2019
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (2) , 461-471
Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide
Tumor-targeted drug delivery systems offer not only the advantage of an enhanced therapeutic index, but also the possibility of overcoming the limitations that have largely restricted drug design to small, hydrophobic, “drug-like” molecules. Here, we explore the ability of a tumor-targeted delivery system centered on the use of a pH-low insertion peptide (pHLIP) to directly deliver moderately polar, multi-kDa molecules into tumor cells. A pHLIP is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pHLIPs target the acidic tumor microenvironment with high specificity, and a drug attached to the inserting end of a pHLIP can be translocated across the cell membrane during the insertion process. We investigate the ability of wildtype pHLIP to deliver peptide nucleic acid (PNA) cargoes of varying sizes across lipid membranes. We find that pHLIP effectively delivers PNAs up to ∼7 kDa into cells in a pH-dependent manner. In addition, pHLIP retains its tumor-targeting capabilities when linked to cargoes of this size, although the amount delivered is reduced for PNA cargoes greater than ∼6 kDa. As drug-like molecules are traditionally restricted to sizes of ∼500 Da, this constitutes an order-of-magnitude expansion in the size range of deliverable drug candidates.
- 1 December 2018
- Published by Elsevier in Trends in Biotechnology
- Vol. 36 (12) , 1300
Applications of pHLIP Technology for Cancer Imaging and Therapy
- 1 December 2018
- Published by Elsevier in Trends in Biotechnology
- Vol. 36 (12) , 1300
Applications of pHLIP Technology for Cancer Imaging and Therapy
- 1 May 2018
- Published by Elsevier in Biophysical Journal
- Vol. 114 (9) , 2107-2115
Bilayer Thickness and Curvature Influence Binding and Insertion of a pHLIP Peptide
- 1 May 2018
- Published by Elsevier in Biophysical Journal
- Vol. 114 (9) , 2107-2115
Bilayer Thickness and Curvature Influence Binding and Insertion of a pHLIP Peptide
- Open Access
- 5 March 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (12) , 201715350-E2818
Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors
The pH (low) insertion peptides (pHLIPs) target acidity at the surfaces of cancer cells and show utility in a wide range of applications, including tumor imaging and intracellular delivery of therapeutic agents. Here we report pHLIP constructs that significantly improve the targeted delivery of agents into tumor cells. The investigated constructs include pHLIP bundles (conjugates consisting of two or four pHLIP peptides linked by polyethylene glycol) and Var3 pHLIPs containing either the nonstandard amino acid, γ-carboxyglutamic acid, or a glycine−leucine−leucine motif. The performance of the constructs in vitro and in vivo was compared with previous pHLIP variants. A wide range of experiments was performed on nine constructs including (i) biophysical measurements using steady-state and kinetic fluorescence, circular dichroism, and oriented circular dichroism to study the pH-dependent insertion of pHLIP variants across the membrane lipid bilayer; (ii) cell viability assays to gauge the pH-dependent potency of peptide-toxin constructs by assessing the intracellular delivery of the polar, cell-impermeable cargo molecule amanitin at physiological and low pH (pH 7.4 and 6.0, respectively); and (iii) tumor targeting and biodistribution measurements using fluorophore-peptide conjugates in a breast cancer mouse model. The main principles of the design of pHLIP variants for a range of medical applications are discussed. Significance Targeted delivery has been limited by reliance on tumor cell biomarkers. The emergence of the pH (low) insertion peptide (pHLIP) technology provides an alternative by targeting a metabolic marker, tumor cell surface acidity. We report several new pHLIPs, including a new concept, pHLIP bundles, and we evaluate these constructs alongside a new generation of pHLIPs. We also discuss challenges inherent to the design and accurate evaluation of pHLIPs. Our research elucidates the strengths and weaknesses of existing pHLIPs, proposes future peptide modifications that could further improve tumor targeting, and discusses the applicability of this new generation of pHLIPs for specific areas of drug delivery. The principles and new constructs promise to advance applications to tumor therapy.
- 5 March 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (12) , 201715350-E2818
Open AccessPeptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors
The pH (low) insertion peptides (pHLIPs) target acidity at the surfaces of cancer cells and show utility in a wide range of applications, including tumor imaging and intracellular delivery of therapeutic agents. Here we report pHLIP constructs that significantly improve the targeted delivery of agents into tumor cells. The investigated constructs include pHLIP bundles (conjugates consisting of two or four pHLIP peptides linked by polyethylene glycol) and Var3 pHLIPs containing either the nonstandard amino acid, γ-carboxyglutamic acid, or a glycine−leucine−leucine motif. The performance of the constructs in vitro and in vivo was compared with previous pHLIP variants. A wide range of experiments was performed on nine constructs including (i) biophysical measurements using steady-state and kinetic fluorescence, circular dichroism, and oriented circular dichroism to study the pH-dependent insertion of pHLIP variants across the membrane lipid bilayer; (ii) cell viability assays to gauge the pH-dependent potency of peptide-toxin constructs by assessing the intracellular delivery of the polar, cell-impermeable cargo molecule amanitin at physiological and low pH (pH 7.4 and 6.0, respectively); and (iii) tumor targeting and biodistribution measurements using fluorophore-peptide conjugates in a breast cancer mouse model. The main principles of the design of pHLIP variants for a range of medical applications are discussed. Significance Targeted delivery has been limited by reliance on tumor cell biomarkers. The emergence of the pH (low) insertion peptide (pHLIP) technology provides an alternative by targeting a metabolic marker, tumor cell surface acidity. We report several new pHLIPs, including a new concept, pHLIP bundles, and we evaluate these constructs alongside a new generation of pHLIPs. We also discuss challenges inherent to the design and accurate evaluation of pHLIPs. Our research elucidates the strengths and weaknesses of existing pHLIPs, proposes future peptide modifications that could further improve tumor targeting, and discusses the applicability of this new generation of pHLIPs for specific areas of drug delivery. The principles and new constructs promise to advance applications to tumor therapy.
- 14 August 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (35) , E7262-E7271
Two transmembrane dimers of the bovine papillomavirus E5 oncoprotein clamp the PDGF β receptor in an active dimeric conformation
Significance: Highly specific protein–protein interactions between transmembrane domains play crucial roles in many biological processes, but are difficult to study because they occur within membranes. The E5 protein of bovine papillomavirus is a 44-residue transmembrane protein that transforms cells by binding the transmembrane domain of the PDGF receptor, resulting in receptor activation. By combining computational modeling, genetic analysis, and biochemical studies, we propose a quaternary structure of the complex between the E5 protein and the PDGF receptor, in which two dimers of the E5 protein clamp two molecules of the receptor transmembrane domain into an active dimeric conformation. These studies reveal the molecular mechanism of action of an unusual oncogene and provide a pathway to study biologically interesting transmembrane complexes.
- 14 August 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (35) , E7262-E7271
Two transmembrane dimers of the bovine papillomavirus E5 oncoprotein clamp the PDGF β receptor in an active dimeric conformation
Significance: Highly specific protein–protein interactions between transmembrane domains play crucial roles in many biological processes, but are difficult to study because they occur within membranes. The E5 protein of bovine papillomavirus is a 44-residue transmembrane protein that transforms cells by binding the transmembrane domain of the PDGF receptor, resulting in receptor activation. By combining computational modeling, genetic analysis, and biochemical studies, we propose a quaternary structure of the complex between the E5 protein and the PDGF receptor, in which two dimers of the E5 protein clamp two molecules of the receptor transmembrane domain into an active dimeric conformation. These studies reveal the molecular mechanism of action of an unusual oncogene and provide a pathway to study biologically interesting transmembrane complexes.